The Effects of Different Ventilation Modes on Patients With Pulmonary Lobe Resection

The Effects of Different Ventilation Modes on Patients With Plasma Inflammatory Factor and Respiratory Function in Patients With Pulmonary Lobe Resection

The objective of this study was to discuss the effects of different ventilation modes on patients with plasma inflammatory factor and respiratory function in patients with pulmonary removal.

Patients who meet the inclusion criteria will be numbered in the order of admission, and a dedicated person will prepare codes and opaque envelopes for random allocation. This study was divided into 3 groups, one groups was ventilation side volume control ventilation+continuous positive pressure ventilation on the non ventilation side, the other groups was ventilation side volume control ventilation+continuous positive pressure ventilation on the non ventilation side; the other groups was ventilation side pressure regulated volume control ventilation+continuous positive pressure ventilation on the non ventilation side.

Inclusion Criteria:

Comprehensive examination and analysis of imaging, laboratory examination and other comprehensive examinations, the diagnosis is clear, which is in line with lobe resection surgical indications

Age 18-75 years old, the gender is not limited;

ASA grading Ⅰ ~ III level;

It is expected that the single lung ventilation time is ≥1 hours, and ≤3 hours

Exclusion Criteria:

Emergency surgery;

There is a taboos on the existence of systemic anesthesia;

There is a history of acute chronic upper respiratory infections in the past January;

Previous bronchial asthma, chronic obstructive pulmonary disease, bronchial dilatation, phthisis ,aspergillosis , acute respiratory distress syndrome or history of respiratory failure;

Merge the function of important organs such as heart, liver, and kidney;

There was a history of chest surgery and the history of trauma;

Preoperative lung function test obvious abnormal abnormal abnormalities (1 second of exhalation (FEV1) <60%);

Patients refuse to participate in the clinical trial